MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by EL-FAKAHANY, E.
Right arrow Articles by RICHELSON, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by EL-FAKAHANY, E.
Right arrow Articles by RICHELSON, E.

Molecular Pharmacology, Vol 19, 282-290, Copyright © 1981 by the American Society for Pharmacology and Experimental Therapeutics

Effects of Lanthanides on Muscarinic Acetylcholine Receptor Function

ESAM EL-FAKAHANY 1 and ELLIOTT RICHELSON 1

1 Departments of Psychiatry and Pharmacology, Mayo Foundation, Rochester, Minnesota 55901

Incubation of mouse neuroblastoma cells (clone N1E-115) with the lanthanides terbium, europium, neodymium, and lanthanum resulted in a concentration-dependent reduction in the maximal cyclic GMP response to full agonists of the muscarinic acetylcholine receptor, and an increase in the response to partial agonists. At 1 mM concentration these lanthanides also caused a significant decrease in the EC50 of the agonists, which was accompanied by a significant reduction in the binding affinity of the 3H-labeled antagonist quinuclidinyl benzilate (QNB), as determined for both mouse neuroblastoma cells and rat brain homogenates. However, this concentration of the lanthanides did not cause a significant change in the agonist equilibrium dissociation constant. The rank order of potency of the lanthanides for their effects on the EC50 for agonists and on the affinity of the antagonist was Tb3+ > Eu3+ > Nd3+ > La3+. Calcium ions mimicked the effects of lanthanides on the EC50 but had opposite effects on maximal responses. In addition, high calcium concentrations decreased the effects of Tb3+ on the EC50 and on [3H]QNB binding with no change in their effect on maximal cyclic GMP responses. We conclude that these lanthanides increase the efficacy of agonists, probably by interacting with Ca2+ binding sites on a factor which couples the receptor to the calcium channels; and that the lanthanides reduce maximal cyclic GMP responses to agonists by interacting with the calcium channels.

Submitted on June 23, 1980
Accepted on October 20, 1980







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1981 by the American Society for Pharmacology and Experimental Therapeutics